Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × conatumumab × Sarcoma × Clear all
NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

Phase 1/2 Terminated
89 enrolled 20 charts
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡